Dr. Reddy’s Laboratories has introduced Toripalimab, marketed as Zytorvi®, in India, marking a significant development in the oncology segment. Approved by global regulatory authorities, including the USFDA, EMA, and DCGI, Toripalimab is the first immuno-oncology drug for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Combined with standard chemotherapy, it has shown a 48% reduction in the risk of disease progression or death, offering a superior treatment option.
India ranks among the top five nations globally for NPC cases, with over 6,500 diagnosed annually. In Manipur, where cancer care infrastructure faces challenges, this launch could bridge critical gaps. The drug’s availability offers a much-needed lifeline for patients in the region, known for its higher incidence rates of NPC.
Improved access to advanced therapies is expected to enhance treatment outcomes and support the growing demand for specialized care in Manipur’s healthcare market. M.V. Ramana, CEO of Branded Markets, emphasized the significance of this launch: “Toripalimab is a next-generation PD-1 inhibitor that addresses a critical unmet need for patients in India, particularly in underserved regions.”